• +1-646-491-9876
    • +91-20-67278686

    Search

    TGF Beta Receptor Type 1 Pipeline Review H1 2017

    TGF Beta Receptor Type 1 Pipeline Review H1 2017

    • Report Code ID: RW0001851073
    • Category Life Sciences
    • No. of Pages 47
    • Publication Month Jun-17
    • Publisher Name Global Markets Direct
    TGF Beta Receptor Type 1 (Activin A Receptor Type II Like Protein Kinase Of 53kD or Activin Receptor Like Kinase 5 or Serine/Threonine Protein Kinase Receptor R4 or Transforming Growth Factor Beta Receptor Type I or ALK5 or TGFBR1 or EC 2.7.11.30) - Pipeline Review, H1 2017

    Summary

    TGF Beta Receptor Type 1 (Activin A Receptor Type II Like Protein Kinase Of 53kD or Activin Receptor Like Kinase 5 or Serine/Threonine Protein Kinase Receptor R4 or Transforming Growth Factor Beta Receptor Type I or ALK5 or TGFBR1 or EC 2.7.11.30) pipeline Target constitutes close to 13 molecules. Out of which approximately 11 molecules are developed by companies and remaining by the universities/institutes. The latest report TGF Beta Receptor Type 1 - Pipeline Review, H1 2017, outlays comprehensive information on the TGF Beta Receptor Type 1 (Activin A Receptor Type II Like Protein Kinase Of 53kD or Activin Receptor Like Kinase 5 or Serine/Threonine Protein Kinase Receptor R4 or Transforming Growth Factor Beta Receptor Type I or ALK5 or TGFBR1 or EC 2.7.11.30) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA) , route of administration (RoA) and molecule type.

    TGF Beta Receptor Type 1 (Activin A Receptor Type II Like Protein Kinase Of 53kD or Activin Receptor Like Kinase 5 or Serine/Threonine Protein Kinase Receptor R4 or Transforming Growth Factor Beta Receptor Type I or ALK5 or TGFBR1 or EC 2.7.11.30) - Transforming growth factor beta receptor I is a TGF beta receptor encoded by TGFBR1 gene. It is involved in physiological and pathological processes including cell cycle arrest in epithelial and hematopoietic cells, control of mesenchymal cell proliferation and differentiation, wound healing, extracellular matrix production, immunosuppression and carcinogenesis. Activated TGFBR1 phosphorylates SMAD2 which dissociates from the receptor and interacts with SMAD4. The SMAD2-SMAD4 complex is subsequently translocated to the nucleus where it modulates the transcription of the TGF-beta-regulated genes. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 2, 6 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Gastrointestinal, Musculoskeletal Disorders, Oncology, Dermatology, Central Nervous System, Genito Urinary System And Sex Hormones, Immunology, Respiratory, Toxicology and Undisclosed which include indications Hepatocellular Carcinoma, Inflammatory Bowel Disease, Liver Fibrosis, Myelodysplastic Syndrome, Solid Tumor, Alzheimer's Disease, Androgenic Alopecia, Breast Cancer, Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) , Degenerative Disc Disease, Fibrosis, Glioblastoma Multiforme (GBM) , Inflammation, Kidney Fibrosis, Malignant Glioma, Melanoma, Metastatic Adenocarcinoma of The Pancreas, Non-Small Cell Lung Cancer, Oral Mucositis, Osteoarthritis, Prostate Cancer, Pulmonary Fibrosis, Radiodermatitis, Recurrent Glioblastoma Multiforme (GBM) , Scar, Unspecified and Wounds.

    Furthermore, this report also reviews key players involved in TGF Beta Receptor Type 1 (Activin A Receptor Type II Like Protein Kinase Of 53kD or Activin Receptor Like Kinase 5 or Serine/Threonine Protein Kinase Receptor R4 or Transforming Growth Factor Beta Receptor Type I or ALK5 or TGFBR1 or EC 2.7.11.30) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The report provides a snapshot of the global therapeutic landscape for TGF Beta Receptor Type 1 (Activin A Receptor Type II Like Protein Kinase Of 53kD or Activin Receptor Like Kinase 5 or Serine/Threonine Protein Kinase Receptor R4 or Transforming Growth Factor Beta Receptor Type I or ALK5 or TGFBR1 or EC 2.7.11.30)
    - The report reviews TGF Beta Receptor Type 1 (Activin A Receptor Type II Like Protein Kinase Of 53kD or Activin Receptor Like Kinase 5 or Serine/Threonine Protein Kinase Receptor R4 or Transforming Growth Factor Beta Receptor Type I or ALK5 or TGFBR1 or EC 2.7.11.30) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
    - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
    - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
    - The report reviews key players involved in TGF Beta Receptor Type 1 (Activin A Receptor Type II Like Protein Kinase Of 53kD or Activin Receptor Like Kinase 5 or Serine/Threonine Protein Kinase Receptor R4 or Transforming Growth Factor Beta Receptor Type I or ALK5 or TGFBR1 or EC 2.7.11.30) targeted therapeutics and enlists all their major and minor projects
    - The report assesses TGF Beta Receptor Type 1 (Activin A Receptor Type II Like Protein Kinase Of 53kD or Activin Receptor Like Kinase 5 or Serine/Threonine Protein Kinase Receptor R4 or Transforming Growth Factor Beta Receptor Type I or ALK5 or TGFBR1 or EC 2.7.11.30) targeted therapeutics based on mechanism of action (MoA) , route of administration (RoA) and molecule type
    - The report summarizes all the dormant and discontinued pipeline projects
    - The report reviews latest news and deals related to TGF Beta Receptor Type 1 (Activin A Receptor Type II Like Protein Kinase Of 53kD or Activin Receptor Like Kinase 5 or Serine/Threonine Protein Kinase Receptor R4 or Transforming Growth Factor Beta Receptor Type I or ALK5 or TGFBR1 or EC 2.7.11.30) targeted therapeutics

    Reasons to buy

    - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
    - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
    - Identify and understand the targeted therapy areas and indications for TGF Beta Receptor Type 1 (Activin A Receptor Type II Like Protein Kinase Of 53kD or Activin Receptor Like Kinase 5 or Serine/Threonine Protein Kinase Receptor R4 or Transforming Growth Factor Beta Receptor Type I or ALK5 or TGFBR1 or EC 2.7.11.30)
    - Identify the use of drugs for target identification and drug repurposing
    - Identify potential new clients or partners in the target demographic
    - Develop strategic initiatives by understanding the focus areas of leading companies
    - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
    - Devise corrective measures for pipeline projects by understanding TGF Beta Receptor Type 1 (Activin A Receptor Type II Like Protein Kinase Of 53kD or Activin Receptor Like Kinase 5 or Serine/Threonine Protein Kinase Receptor R4 or Transforming Growth Factor Beta Receptor Type I or ALK5 or TGFBR1 or EC 2.7.11.30) development landscape
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    TGF Beta Receptor Type 1 (Activin A Receptor Type II Like Protein Kinase Of 53kD or Activin Receptor Like Kinase 5 or Serine/Threonine Protein Kinase Receptor R4 or Transforming Growth Factor Beta Receptor Type I or ALK5 or TGFBR1 or EC 2.7.11.30) - Overview
    TGF Beta Receptor Type 1 (Activin A Receptor Type II Like Protein Kinase Of 53kD or Activin Receptor Like Kinase 5 or Serine/Threonine Protein Kinase Receptor R4 or Transforming Growth Factor Beta Receptor Type I or ALK5 or TGFBR1 or EC 2.7.11.30) - Therapeutics Development
    Products under Development by Stage of Development
    Products under Development by Therapy Area
    Products under Development by Indication
    Products under Development by Companies
    Products under Development by Universities/Institutes
    TGF Beta Receptor Type 1 (Activin A Receptor Type II Like Protein Kinase Of 53kD or Activin Receptor Like Kinase 5 or Serine/Threonine Protein Kinase Receptor R4 or Transforming Growth Factor Beta Receptor Type I or ALK5 or TGFBR1 or EC 2.7.11.30) - Therapeutics Assessment
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    TGF Beta Receptor Type 1 (Activin A Receptor Type II Like Protein Kinase Of 53kD or Activin Receptor Like Kinase 5 or Serine/Threonine Protein Kinase Receptor R4 or Transforming Growth Factor Beta Receptor Type I or ALK5 or TGFBR1 or EC 2.7.11.30) - Companies Involved in Therapeutics Development
    Eli Lilly and Company
    SK Chemicals Co Ltd
    Taisho Pharmaceutical Holdings Co Ltd
    Takeda Pharmaceutical Company Ltd
    Yuhan Corp
    TGF Beta Receptor Type 1 (Activin A Receptor Type II Like Protein Kinase Of 53kD or Activin Receptor Like Kinase 5 or Serine/Threonine Protein Kinase Receptor R4 or Transforming Growth Factor Beta Receptor Type I or ALK5 or TGFBR1 or EC 2.7.11.30) - Drug Profiles
    galunisertib - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Monoclonal Antibodies to Antagonize TGF-Beta Receptor Type-1 for HCV associated Liver Fibrosis - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Recombinant Protein to Antagonize TGF beta for Immunology, Dermatology, Gastrointestinal and Musculoskeletal Disorders - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    SKI-2162 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecule to Inhibit TGF Beta Receptor Type 1 for Solid Tumor - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules to Inhibit ALK5 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    SRI-011381 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    TEW-7197 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    TP-0427736 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    TPX-6001 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    TPX-6001 + tretinoin - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    YH-14618 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    YH-14619 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    TGF Beta Receptor Type 1 (Activin A Receptor Type II Like Protein Kinase Of 53kD or Activin Receptor Like Kinase 5 or Serine/Threonine Protein Kinase Receptor R4 or Transforming Growth Factor Beta Receptor Type I or ALK5 or TGFBR1 or EC 2.7.11.30) - Dormant Products
    TGF Beta Receptor Type 1 (Activin A Receptor Type II Like Protein Kinase Of 53kD or Activin Receptor Like Kinase 5 or Serine/Threonine Protein Kinase Receptor R4 or Transforming Growth Factor Beta Receptor Type I or ALK5 or TGFBR1 or EC 2.7.11.30) - Product Development Milestones
    Featured News & Press Releases
    May 18, 2016: Lilly to present data on TGFß small-molecule kinase inhibitor galunisertib at ASCO
    May 14, 2013: Lilly Oncology To Release New Pipeline Data On TGF Beta Inhibitor LY2157299 At ASCO 2013
    Apr 10, 2013: Lilly Presents Data On TGF-beta Inhibitor LY2157299 At AACR Annual Meeting
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development by Stage of Development, H1 2017
    Number of Products under Development by Therapy Areas, H1 2017
    Number of Products under Development by Indications, H1 2017
    Number of Products under Development by Indications, H1 2017 (Contd..1) , H1 2017
    Number of Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017 (Contd..1) , H1 2017
    Number of Products under Investigation by Universities/Institutes, H1 2017
    Products under Investigation by Universities/Institutes, H1 2017
    Number of Products by Stage and Mechanism of Actions, H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Pipeline by Eli Lilly and Company, H1 2017
    Pipeline by SK Chemicals Co Ltd, H1 2017
    Pipeline by Taisho Pharmaceutical Holdings Co Ltd, H1 2017
    Pipeline by Takeda Pharmaceutical Company Ltd, H1 2017
    Pipeline by Yuhan Corp, H1 2017
    Dormant Projects, H1 2017

    List of Figures

    Number of Products under Development by Stage of Development, H1 2017
    Number of Products under Development by Therapy Areas, H1 2017
    Number of Products under Development by Top 10 Indications, H1 2017
    Number of Products by Mechanism of Actions, H1 2017
    Number of Products by Stage and Mechanism of Actions, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Molecule Types, H1 2017
    Number of Products by Stage and Molecule Types, H1 2017
    Eli Lilly and Company
    SK Chemicals Co Ltd
    Taisho Pharmaceutical Holdings Co Ltd
    Takeda Pharmaceutical Company Ltd
    Yuhan Corp

    Request for Sample

    Report Url https://www.reportsweb.com//tgf-beta-receptor-type-1-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url https://www.reportsweb.com//tgf-beta-receptor-type-1-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url https://www.reportsweb.com//tgf-beta-receptor-type-1-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments